Proiecte

Identifying individuals at risk of PROGRESSION to active tuberculosis. NIH - 1R01AI137681-01. PI- Dr. Antonino Catanzaro. University of California, San Diego. Duration - 03.2018-02.2023

Integrated TABLETOP Platform for Rapid Detection of XDR-TB. NIH-NIAID 5R01AI111435-03., PI Dr. Timothy Rodwel. University of California, San Diego. Duration - 06.2016-07.2019.

Genomic, spatial and epidemiological analysis to inform targeted tuberculosis interventions in Moldova

Analiza genomică, spațială și epidemiologică pentru a informare țintită despre intervențiile vizate de TB în Moldova. 1304.FR.03A USAID-UNION. PI-Dr. Ted Cohen. Duration - 2018-2020.

Innovation in Tuberculosis. INNOVA4TB. Horizon 2020. Framework Programme. H2020-MSCA-RISE-2018 (H2020-MSCA-RISE-2018). 823854

Common action against HIV/TB/HCV across the regions of Europe. Horizon 2020. Framework Programme. H2020-SC1-2018-Single-StageRTD). Proposal: 825673

Moldova TB Portal. Tuberculosis recurrence: relapse or reinfection. CRDF Global (U.S. Civilian Research & Development Foundation). Project No: DAA3-17-63406-1. PI Valeriu Crudu; Duration – 2017-2018.

An Antigen-Detection Blood Test for Pulmonary Tuberculosis. Financed by: University of California, San Diego, NIH - 1 R01 AI141500-01. Sub-grantee/contractor: Phthisiopneumology Institute, Chisinau, Moldova. Principal Investigator: Dr. Antonino Catanzaro. Duration - 06.2018-05.2023. SPECTRUM

Protecting Pyrazinamide (PZA) and fluoroquinolones (FLQ) for successful multi drug resistant tuberculosis (MDR-TB) treatment. Financed by: Holland Subsidy programme: Antibiotica Resistentie (ABR). No: 50-54100-98-255; Sub-grantee/contractor: Phthisiopneumology Institute, Chisinau, Moldova. Principal Investigator: Dr. R.M. Anthony; Duration: 2018-2020

Multicentre Clinical Study to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection. Phase II: Foundation for Innovative New Diagnostics. Geneva. 2019